pt en


Innovative peptides against cancer and pathogenic bacteria, with advances in science, biopharmaceutical drug development, product market targeting, training, and communication

Funding Agency European Commission
Funding Programme Horizon 2020
Call/Topic H2020-MSCA-RISE-2014
Project reference 644167
Start date 2015.02.01
Duration 36 months
Total investment EUR 1 390 500 (EU contribution: EUR 850 500)
Project Coordinator Miguel Castanho
Project Beneficiaries

Instituto de Medicina Molecular João Lobo Antunes (iMM), Portugal
Universidad Pompeu Fabra (UPF), Spain
Universidad de Navarra (IESE Business School), Spain
Technophage, Portugal
Centro Atlantico del Medicamento (CEAMED), Spain
ProteoDesign, Spain

Project Partners

Universidade Federal do Rio de Janeiro (UFRJ), Brazil
University of Queensland (UQ), Australia
Stanford University (SU), United Kingdom
Instituto Ciência Hoje (ICH), Brazil


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 644167.

  • Overview

    INPACT aims at the pre-clinical development of innovative drugs and drug formulations against selected cancers (eg prostate cancer) and pathogenic bacteria (eg S. aureus). The INPACT consortium allies the expertise of both academic and industrial R&D partners that contribute with their own unique technologies to achieve new drugs that are only possible to develop in an integrative effort. Academic partners have unique knowledge and technologies on supercharged viral proteins-derived cell-penetrating peptides (eg from Dengue virus) and ultra-resistant cyclic peptides that may be transferred to the industrial partners, which in turn have specialized proprietary technologies on anticancer and/or peptide drugs’ technologies. The judicious exchange of knowledge among partners will lead to new resistant peptides for trans-barrier delivery of drugs (eg cyclic peptide-drug chimeras) and bacterial killing (both planktonic and biofilms). INPACT includes four leading academic partners (from Portugal, Spain, Australia, and Brazil) and three consolidated biotech SMEs (one from Portugal and two Spain).

    In addition to the R&D project itself, INPACT involves at the highest possible level a top business school in Europe (IESE, Barcelona, Spain), a consolidated media partner specialised in science communication (Ciencia Hoje, Rio de Janeiro, Brazil) and experts in international science funding from one of the top US universities (University of Stanford). The consortium will be the perfect environment for young researchers to acquire knowledge and skills in science, technology, entrepreneurship, business, and communication so they can pro-actively tailor their career path in a life-long learning perspective. This is a contribution towards the advancement of Europe through the use of research and education for societal development and economic growth.

  • Project Videos

  • Website

This site uses cookies. Some of the cookies we use are essential for parts of the site to operate and have already been set.
You may delete and block all cookies from this site, but parts of the site will not work.